No, Medicare does not cover genetic testing to learn future dementia risk when you have no symptoms. It can cover APOE testing when a doctor orders it to guide Alzheimer's treatment.
APOE testing looks at a gene variant that affects Alzheimer's risk and treatment safety. Standalone risk testing estimates what might happen later. Treatment testing helps decide care now.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Check eligibility on Medicare’s official study page — Use this page to check the study’s participation requirements.
- Explore the official data from CMS — Use this primary source to review the underlying data.
Table of Contents
- Why risk-only testing does not qualify
- When APOE testing can fit treatment
- What the Alzheimer's drug pathway requires
- How to get the right order and avoid scams
Why risk-only testing does not qualify
Medicare.gov states that Part B covers only medically necessary lab tests ordered by a treating provider to diagnose or rule out suspected illness, described in Medicare's diagnostic laboratory test rules. Predictive screening in people without symptoms does not meet that test. Chapter reports the same result for standalone APOE dementia-risk testing.
A routine checkup request is therefore not enough. Curiosity about family risk is not enough. The order must connect to a current medical decision.
When APOE testing can fit treatment
Coverage becomes possible when APOE testing guides use of lecanemab or donanemab, sold as Leqembi and Kisunla. The CMS coding article lists APOE code 81401 for Alzheimer's disease as an FDA-indicated use with those drugs, detailed in the CMS coding article for pharmacogenomic testing.
Eisai reports that FDA prescribing information for lecanemab directs APOE ε4 testing before treatment to inform risk of amyloid-related imaging abnormalities, or ARIA, explained in Eisai's FDA approval announcement for Leqembi. ARIA means brain swelling or microbleeds. The same source places highest risk in APOE ε4 homozygotes, about 15% of Alzheimer's patients.
What the Alzheimer's drug pathway requires
CMS covers FDA traditionally approved amyloid antibodies only under coverage with evidence development. Patients must have mild cognitive impairment or mild dementia with confirmed amyloid pathology. The clinician must take part in a registry.
That pathway shapes the test order. The record should show cognitive impairment now. It should show amyloid confirmation. It should show registry participation for the drug decision.
How to get the right order and avoid scams
Ask your own doctor whether APOE testing would change treatment. Confirm coverage before testing if the order is uncertain. Chapter notes that without a doctor's order and documented treatment consideration, beneficiaries face out-of-pocket payment.
Watch for fraud offers at the same time. HHS-OIG warns about "free" cheek-swab screenings for Alzheimer's, dementia, cancer, or cardiac risk offered by phone, mail, or health fairs, described in the HHS-OIG fraud alert on genetic testing scams. Decline the swab and do not share your Medicare number with a cold caller.
- A caller offers a free dementia gene test.
- The offer comes outside your doctor's office.
- You are asked for your Medicare number.
- No treating doctor ordered the test.
